Search
Mitapivat
go.drugbank.com/drugs/DB16236ApprovedInvestigational[A245478] On January 5, 2026, the FDA also approved the use of in the treatment of anemia in adults with alpha- or beta-thalassemia, making it the first oral treatment for this condition.[L54953] … Defects in the pyruvate kinase enzyme in various red blood cells disorders lead to the lack of energy production for red blood cells, leading to lifelong premature destruction of red blood cells or chronic
Abrocitinib
go.drugbank.com/drugs/DB14973ApprovedInvestigational[A244549] Abrocitinib was approved by the European Commission on December 10, 2021, for the treatment of moderate-to-severe atopic dermatitis (AD) in adults who are candidates for systemic therapy. … JAK inhibitors recently attracted more attention as potential treatments for inflammatory disorders, as JAK inhibition is associated with rapid and sustained anti-inflammatory efects.
Categories: Agents for Dermatitis, Excluding CorticosteroidsMagnesium carbonate
go.drugbank.com/drugs/DB09481ApprovedMagnesium carbonate, also known as magnesite, is a common over the counter remedy for heartburn and upset stomach caused by overproduction of acid in the stomach [FDA Label].
Categories: Drugs for Constipation, Drugs for Acid Related DisordersTrilaciclib
go.drugbank.com/drugs/DB15442ApprovedInvestigationalG1T28, is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing chemotherapy for … [L31828] CDK4 and CDK6 inhibitors have been investigated since the mid 1990s for their use in tumorigenesis and chemotherapy.[A229323] Trilaciclib was first described in the literature in 2016.
Categories: Detoxifying Agents for Antineoplastic TreatmentRelugolix
go.drugbank.com/drugs/DB11853ApprovedInvestigationalOrgovyx, for the treatment of advanced prostate cancer. … [A225761] Relugolix is the first (and currently only) orally-administered GnRH receptor antagonist approved for the treatment of prostate cancer - similar therapies such as [degarelix] require subcutaneous
Categories: Gonadotropin Releasing Hormone Receptor AntagonistsChromium picolinate
go.drugbank.com/drugs/DB11255ApprovedChromium picolinate is used as a nutritional supplement for optimal insulin function in patients with Type 2 diabetes or promotion of weight loss. … Chromium ions are shown to regulate insulin by promoting glucose utilization and increasing the sensitivity of the insulin receptor [A27235].
Mixtures: BLACKMORES teen multi for GUYS capsuleAlfentanil
go.drugbank.com/drugs/DB00802ApprovedIllicitInvestigationalAlfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients.
Valine
go.drugbank.com/drugs/DB00161ApprovedInvestigationalNutraceuticalValine is a branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.
Mixtures: GLAMIN SOLUTION FOR INFUSION, KABIVEN EMULSION FOR INFUSIONHexylresorcinol
go.drugbank.com/drugs/DB11254ApprovedIt can be found in topical applications for minor skin infections and in oral solutions or throat lozenges for pain relief and first aid antiseptic.
Vimseltinib
go.drugbank.com/drugs/DB17520ApprovedInvestigational[L52230,A265035] Vimseltinib - under the brand name Romvimza - was approved by the FDA in February 2025 for the treatment of tenosynovial giant cell tumours for which surgical resection is not appropriate … [L52230] It is highly selective, with a >500-fold selectivity for CSF1R over its nearest off-target kinase.